Adaptimmune Therapeutics (ADAP) Stock Forecast, Price Target & Predictions
ADAP Stock Forecast
Adaptimmune Therapeutics stock forecast is as follows: an average price target of $2.83 (represents a 154.95% upside from ADAP’s last price of $1.11) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
ADAP Price Target
The average price target for Adaptimmune Therapeutics (ADAP) is $2.83 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $1.00. This represents a potential 154.95% upside from ADAP's last price of $1.11.
ADAP Analyst Ratings
According to 5 Wall Street analysts, Adaptimmune Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ADAP stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 1 'Hold' (20.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).
Adaptimmune Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 30, 2024 | Arthur He | H.C. Wainwright | $4.00 | $1.37 | 191.97% | 260.36% |
| May 30, 2024 | George Farmer | Scotiabank | $3.15 | $1.01 | 211.88% | 183.78% |
| May 17, 2024 | Graig Suvannavejh | Mizuho Securities | $3.00 | $1.20 | 150.00% | 170.27% |
| May 16, 2024 | Peter Lawson | Barclays | $1.00 | $1.20 | -16.67% | -9.91% |
| Nov 14, 2022 | - | Wells Fargo | $3.00 | $2.51 | 19.52% | 170.27% |
The latest Adaptimmune Therapeutics stock forecast, released on Jul 30, 2024 by Arthur He from H.C. Wainwright, set a price target of $4.00, which represents a 191.97% increase from the stock price at the time of the forecast ($1.37), and a 260.36% increase from ADAP last price ($1.11).
Adaptimmune Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $4.00 | $2.79 |
| Last Closing Price | $1.11 | $1.11 | $1.11 |
| Upside/Downside | -100.00% | 260.36% | 151.35% |
In the current month, the average price target of Adaptimmune Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Adaptimmune Therapeutics's last price of $1.11. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 05, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
| Aug 05, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jul 30, 2024 | H.C. Wainwright | - | Buy | Initialise |
| May 31, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| May 30, 2024 | Scotiabank | - | Outperform | Initialise |
| May 16, 2024 | Barclays | Underweight | Underweight | Hold |
| Jan 03, 2023 | Guggenheim | - | Buy | Upgrade |
| Nov 09, 2022 | Bank of America Securities | - | Buy | Upgrade |
| Nov 09, 2022 | Mizuho Securities | - | Buy | Upgrade |
Adaptimmune Therapeutics's last stock rating was published by Scotiabank on Aug 05, 2024. The company gave ADAP a "Sector Outperform" rating, the same as its previous rate.
Adaptimmune Therapeutics Financial Forecast
Adaptimmune Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $231.00K | $7.32M | $5.13M | $47.60M | $11.03M | $7.01M | $5.54M | $3.58M | $1.42M | $1.20M | $3.10M | $434.00K | $1.50M | $1.19M | $502.00K | $761.00K | $728.00K | $237.00K |
| Avg Forecast | $629.08M | $536.64M | $457.79M | $390.52M | $11.33M | $9.23M | $7.63M | $6.23M | $11.08M | $18.57M | $40.47M | $9.88M | $25.96M | $7.97M | $6.13M | $5.15M | $3.83M | $6.93M | $6.57M | $3.50M | $4.50M | $1.53M | $1.40M | $1.83M | $1.80M | $1.02M | $7.94M | $23.29M | $1.30M | $1.48M |
| High Forecast | $629.08M | $536.64M | $457.79M | $390.52M | $11.33M | $9.23M | $7.63M | $6.23M | $11.08M | $22.91M | $40.47M | $9.88M | $25.96M | $7.97M | $6.13M | $5.15M | $3.83M | $6.93M | $6.57M | $4.93M | $6.34M | $2.16M | $1.97M | $2.58M | $2.54M | $1.43M | $11.19M | $32.80M | $1.83M | $2.08M |
| Low Forecast | $629.08M | $536.64M | $457.79M | $390.52M | $11.33M | $9.23M | $7.63M | $6.23M | $11.08M | $14.23M | $40.47M | $9.88M | $25.96M | $7.97M | $6.13M | $5.15M | $3.83M | $6.93M | $6.57M | $1.79M | $2.30M | $783.97K | $715.80K | $937.36K | $920.32K | $519.81K | $4.06M | $11.91M | $664.67K | $756.70K |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.01% | 0.92% | 0.84% | 9.24% | 2.88% | 1.01% | 0.84% | 1.02% | 0.31% | 0.78% | 2.21% | 0.24% | 0.83% | 1.17% | 0.06% | 0.03% | 0.56% | 0.16% |
Adaptimmune Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $9.88M, with a low forecast of $9.88M, and a high forecast of $9.88M. ADAP's average Quarter revenue forecast represents a 4177.06% increase compared to the company's last Quarter revenue of $231.00K (Dec 23).
Adaptimmune Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-47.26M | $-46.29M | $-64.83M | $3.50M | $-27.24M | $-41.50M | $-42.20M | $-48.39M | $-36.41M | $-40.74M | $-37.55M | $-36.03M | $-34.84M | $-33.59M | $-27.70M | $-26.21M | $-27.18M | $-37.27M |
| Avg Forecast | $-629.08M | $-536.64M | $-457.79M | $-390.52M | $-11.33M | $-9.23M | $-7.63M | $-6.23M | $-11.08M | $-18.57M | $-40.47M | $-26.54M | $-25.96M | $-7.97M | $-6.13M | $-28.38M | $-3.83M | $-38.09M | $-6.57M | $-30.35M | $-4.50M | $-40.74M | $-39.05M | $-37.47M | $-33.32M | $-34.94M | $-25.57M | $-25.36M | $-29.88M | $-30.55M |
| High Forecast | $-629.08M | $-536.64M | $-457.79M | $-390.52M | $-11.33M | $-9.23M | $-7.63M | $-6.23M | $-11.08M | $-14.23M | $-40.47M | $-21.23M | $-25.96M | $-7.97M | $-6.13M | $-22.70M | $-3.83M | $-30.47M | $-6.57M | $-24.28M | $-2.30M | $-32.59M | $-31.24M | $-29.98M | $-26.66M | $-27.95M | $-20.46M | $-20.29M | $-23.90M | $-24.44M |
| Low Forecast | $-629.08M | $-536.64M | $-457.79M | $-390.52M | $-11.33M | $-9.23M | $-7.63M | $-6.23M | $-11.08M | $-22.91M | $-40.47M | $-31.84M | $-25.96M | $-7.97M | $-6.13M | $-34.06M | $-3.83M | $-45.71M | $-6.57M | $-36.42M | $-6.34M | $-48.89M | $-46.86M | $-44.96M | $-39.99M | $-41.93M | $-30.69M | $-30.43M | $-35.86M | $-36.66M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.82% | 5.81% | 10.58% | -0.12% | 7.11% | 1.09% | 6.42% | 1.59% | 8.09% | 1.00% | 0.96% | 0.96% | 1.05% | 0.96% | 1.08% | 1.03% | 0.91% | 1.22% |
1 analysts predict ADAP's average Quarter EBITDA for Jun 23 to be $-6.13M, with a high of $-6.13M and a low of $-6.13M. This is -275.05% lower than Adaptimmune Therapeutics's previous annual EBITDA (Mar 23) of $3.50M.
Adaptimmune Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-47.92M | $-45.60M | $-21.39M | $1.04M | $-29.25M | $-41.42M | $-44.52M | $-50.27M | $-38.86M | $-42.40M | $-39.07M | $-37.76M | $-36.61M | $-35.43M | $-29.88M | $-28.17M | $-29.36M | $-39.30M |
| Avg Forecast | $-42.77M | $-44.10M | $-47.63M | $-48.96M | $-31.96M | $-32.76M | $-32.42M | $-33.22M | $-7.42M | $-3.12M | $-11.39M | $-27.96M | $-42.88M | $-50.41M | $-37.72M | $-29.91M | $-63.67M | $-39.64M | $-70.14M | $-31.99M | $27.71M | $-42.40M | $-40.63M | $-39.27M | $-35.02M | $-36.83M | $-28.58M | $-29.29M | $-32.82M | $-32.96M |
| High Forecast | $-42.77M | $-44.10M | $-47.63M | $-48.96M | $-31.96M | $-32.76M | $-32.42M | $-33.22M | $-7.42M | $-1.84M | $-11.39M | $-22.37M | $-25.01M | $-50.41M | $-37.72M | $-23.93M | $-63.67M | $-31.72M | $-70.14M | $-25.59M | $42.43M | $-33.92M | $-32.50M | $-31.42M | $-28.02M | $-29.47M | $-22.86M | $-23.43M | $-26.25M | $-26.37M |
| Low Forecast | $-42.77M | $-44.10M | $-47.63M | $-48.96M | $-31.96M | $-32.76M | $-32.42M | $-33.22M | $-7.42M | $-4.41M | $-11.39M | $-33.56M | $-57.17M | $-50.41M | $-37.72M | $-35.89M | $-63.67M | $-47.57M | $-70.14M | $-38.38M | $10.10M | $-50.88M | $-48.76M | $-47.13M | $-42.03M | $-44.20M | $-34.30M | $-35.15M | $-39.38M | $-39.56M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.12% | 0.90% | 0.57% | -0.03% | 0.46% | 1.04% | 0.63% | 1.57% | -1.40% | 1.00% | 0.96% | 0.96% | 1.05% | 0.96% | 1.05% | 0.96% | 0.89% | 1.19% |
Adaptimmune Therapeutics's average Quarter net income forecast for Jun 23 is $-37.72M, with a range of $-37.72M to $-37.72M. ADAP's average Quarter net income forecast represents a -3740.85% decrease compared to the company's last Quarter net income of $1.04M (Mar 23).
Adaptimmune Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $16.88M | $16.16M | $20.07M | $20.40M | $15.22M | $16.82M | $16.89M | $16.80M | $15.48M | $15.17M | $14.99M | $13.82M | $13.24M | $13.00M | $10.29M | $9.26M | $10.73M | $10.74M |
| Avg Forecast | $7.88B | $6.72B | $5.74B | $4.89B | $142.02M | $115.70M | $95.65M | $78.11M | $138.84M | $232.70M | $507.13M | $9.35M | $325.30M | $99.89M | $76.80M | $64.53M | $48.04M | $86.82M | $82.35M | $43.86M | $56.39M | $19.21M | $17.54M | $22.97M | $22.56M | $12.74M | $99.53M | $9.63M | $16.29M | $18.55M |
| High Forecast | $7.88B | $6.72B | $5.74B | $4.89B | $142.02M | $115.70M | $95.65M | $78.11M | $138.84M | $287.05M | $507.13M | $11.22M | $325.30M | $99.89M | $76.80M | $64.53M | $48.04M | $86.82M | $82.35M | $61.79M | $79.44M | $27.07M | $24.71M | $32.36M | $31.78M | $17.95M | $140.22M | $11.56M | $22.95M | $26.13M |
| Low Forecast | $7.88B | $6.72B | $5.74B | $4.89B | $142.02M | $115.70M | $95.65M | $78.11M | $138.84M | $178.35M | $507.13M | $7.48M | $325.30M | $99.89M | $76.80M | $64.53M | $48.04M | $86.82M | $82.35M | $22.42M | $28.83M | $9.82M | $8.97M | $11.75M | $11.53M | $6.51M | $50.89M | $7.71M | $8.33M | $9.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.05% | 0.16% | 0.26% | 0.32% | 0.32% | 0.19% | 0.21% | 0.38% | 0.27% | 0.79% | 0.85% | 0.60% | 0.59% | 1.02% | 0.10% | 0.96% | 0.66% | 0.58% |
Adaptimmune Therapeutics's average Quarter SG&A projection for Mar 24 is $9.35M, based on 1 Wall Street analysts, with a range of $7.48M to $11.22M. The forecast indicates a -44.61% fall compared to ADAP last annual SG&A of $16.88M (Dec 23).
Adaptimmune Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.34 | $-0.12 | $0.01 | $-0.18 | $-0.25 | $-0.28 | $-0.32 | $-0.25 | $-0.27 | $-0.25 | $-0.24 | $-0.24 | $-0.23 | $-0.22 | $-0.23 | $-0.28 | $-0.37 |
| Avg Forecast | $-0.16 | $-0.17 | $-0.18 | $-0.19 | $-0.12 | $-0.13 | $-0.12 | $-0.13 | $-0.03 | $-0.01 | $-0.04 | $-0.15 | $-0.17 | $-0.19 | $-0.15 | $-0.19 | $-0.24 | $-0.25 | $-0.29 | $-0.25 | $0.12 | $-0.26 | $-0.04 | $-0.04 | $-0.23 | $-0.25 | $-0.24 | $-0.25 | $-0.34 | $-0.30 |
| High Forecast | $-0.16 | $-0.17 | $-0.18 | $-0.19 | $-0.12 | $-0.13 | $-0.12 | $-0.13 | $-0.03 | $-0.01 | $-0.04 | $-0.15 | $-0.10 | $-0.19 | $-0.15 | $-0.19 | $-0.24 | $-0.25 | $-0.29 | $-0.09 | $0.19 | $-0.10 | $-0.01 | $-0.01 | $-0.09 | $-0.09 | $-0.09 | $-0.09 | $-0.12 | $-0.11 |
| Low Forecast | $-0.16 | $-0.17 | $-0.18 | $-0.19 | $-0.12 | $-0.13 | $-0.12 | $-0.13 | $-0.03 | $-0.02 | $-0.04 | $-0.15 | $-0.22 | $-0.19 | $-0.15 | $-0.19 | $-0.24 | $-0.25 | $-0.29 | $-0.39 | $0.04 | $-0.40 | $-0.06 | $-0.06 | $-0.36 | $-0.39 | $-0.36 | $-0.39 | $-0.52 | $-0.47 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.75% | 0.83% | -0.03% | 0.73% | 1.00% | 0.97% | 1.26% | -2.05% | 1.02% | 6.67% | 6.48% | 1.03% | 0.91% | 0.93% | 0.91% | 0.82% | 1.21% |
According to 1 Wall Street analysts, Adaptimmune Therapeutics's projected average Quarter EPS for Jun 23 is $-0.15, with a low estimate of $-0.15 and a high estimate of $-0.15. This represents a -2403.97% decrease compared to ADAP previous annual EPS of $0.01 (Mar 23).
Adaptimmune Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACET | Adicet Bio | $1.49 | $32.50 | 2081.21% | Buy |
| SGMO | Sangamo Therapeutics | $0.85 | $12.00 | 1311.76% | Hold |
| NKTX | Nkarta | $5.71 | $21.60 | 278.28% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| ADAP | Adaptimmune Therapeutics | $1.11 | $2.83 | 154.95% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| LPTX | Leap Therapeutics | $2.74 | $5.50 | 100.73% | Buy |
| AFMD | Affimed | $4.00 | $7.50 | 87.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| CRVS | Corvus Pharmaceuticals | $5.10 | $7.00 | 37.25% | Buy |
| AGIO | Agios Pharmaceuticals | $46.69 | $47.50 | 1.73% | Buy |
ADAP Forecast FAQ
Is Adaptimmune Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Adaptimmune Therapeutics (ADAP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of ADAP's total ratings.
What is ADAP's price target?
Adaptimmune Therapeutics (ADAP) average price target is $2.83 with a range of $1 to $4, implying a 154.95% from its last price of $1.11. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Adaptimmune Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ADAP stock, the company can go up by 154.95% (from the last price of $1.11 to the average price target of $2.83), up by 260.36% based on the highest stock price target, and down by -9.91% based on the lowest stock price target.
Can Adaptimmune Therapeutics stock reach $2?
ADAP's average twelve months analyst stock price target of $2.83 supports the claim that Adaptimmune Therapeutics can reach $2 in the near future.
What are Adaptimmune Therapeutics's analysts' financial forecasts?
Adaptimmune Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $34.43M (high $34.43M, low $34.43M), average EBITDA is $-34.433M (high $-34.433M, low $-34.433M), average net income is $-130M (high $-130M, low $-130M), average SG&A $431.48M (high $431.48M, low $431.48M), and average EPS is $-0.502 (high $-0.502, low $-0.502). ADAP's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.01B (high $2.01B, low $2.01B), average EBITDA is $-2.014B (high $-2.014B, low $-2.014B), average net income is $-183M (high $-183M, low $-183M), average SG&A $25.24B (high $25.24B, low $25.24B), and average EPS is $-0.706 (high $-0.706, low $-0.706).
Did the ADAP's actual financial results beat the analysts' financial forecasts?
Based on Adaptimmune Therapeutics's last annual report (Dec 2023), the company's revenue was $60.28M, beating the average analysts forecast of $45.21M by 33.34%. Apple's EBITDA was $-115M, beating the average prediction of $-68.44M by 68.33%. The company's net income was $-114M, missing the average estimation of $-161M by -29.24%. Apple's SG&A was $73.51M, missing the average forecast of $566.52M by -87.02%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.69 by -99.99%. In terms of the last quarterly report (Dec 2023), Adaptimmune Therapeutics's revenue was $231K, missing the average analysts' forecast of $25.96M by -99.11%. The company's EBITDA was $-47.261M, beating the average prediction of $-25.96M by 82.05%. Adaptimmune Therapeutics's net income was $-47.917M, beating the average estimation of $-42.878M by 11.75%. The company's SG&A was $16.88M, missing the average forecast of $325.3M by -94.81%. Lastly, the company's EPS was $0, missing the average prediction of $-0.165 by -100.00%